Typar TCV IM Injection
Typhoid Conjugate Vaccine
0.5 ml/vial
Renata PLC.
| Pack size | 0.5 ml vial |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 2500.00 AED |
Indications
Typar TCV IM Injection is used for:
Active immunization against Typhoid infection
Adult Dose
Adults aged <45 years.
Intramuscular
A single 0.5 mL IM dose
Child Dose
Infants, children, and adolescents aged >6 months.
Intramuscular
A single 0.5 mL IM dose
Renal Dose
Administration
The vaccine should be administered intramuscularly in the deltoid muscle of the upper arm if muscle mass is adequate for children 2 years and above, adolescents and adults.
For infants and toddlers aged >6 months to <2 years of age, the vaccine should be administered intramuscularly in the vastus lateralis muscle on anterolateral aspect of thigh.
This vaccine should not be injected into the gluteal area or in any areas where there may be a nerve trunk.
Contra Indications
Hypersensitivity to any component of the vaccine
Pregnant & lactating women
In case of fever and severe infection
Precautions
Do not administer intravenously, intradermally or subcutaneously.
Typhoid Conjugate Vaccine protects against typhoid fever caused by Salmonella typhi. Protection is not conferred against Salmonella paratyphi and other non typhoidal Salmonellae.
Pregnancy-Lactation
Safety and effectiveness have not been established in pregnant women and in nursing mothers. It is not known whether the vaccine is excreted in human milk.
Interactions
Adverse Effects
Side effects of Typhoid Conjugate Vaccine :
The most frequently reported local adverse events after administration of Typhoid Conjugate Vaccine were Injection Site Pain (4.50%), Injection Site erythema (0.64%) and Injection site Swelling (0.32%). These usually occurred within first 48 hours and disappeared within 2-3 days.
The most frequently reported systemic adverse events were Pyrexia (2.25%), Vomiting (0.96%), Headache (0.64%), Fatigue (0.64%), Arthralgia (0.32%) and Rash (0.32%). No vaccine-related serious adverse events (SAEs) were reported in the clinical trial.
Mechanism of Action
Typhoid Vi Conjugate Vaccine is a clear, colorless solution, free from visible particulate matter. The vaccine contains 25 mcg of Typhoid Vi polysaccharide conjugated to CRMt97. The polysaccharide is manufactured using Citrobacter freundii sensu lato 3056 (Vi) and is conjugated to CRM197 as a carrier protein. Sodium Chloride and Phosphate Buffer are used as a diluent (buffering agent) in vaccine formulation. 2-Phenoxyethanol is added as a preservative.
Note
Typar TCV 0.5 ml/vial IM Injection manufactured by Renata PLC.. Its generic name is Typhoid Conjugate Vaccine. Typar TCV is availble in Bangladesh.
Farmaco BD drug index information on Typar TCV IM Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.